Wasatch Advisors LP Purchases 39,451 Shares of OrthoPediatrics Corp. $KIDS

Wasatch Advisors LP grew its position in OrthoPediatrics Corp. (NASDAQ:KIDS) by 13.6% in the 1st quarter, Holdings Channel reports. The institutional investor owned 329,320 shares of the company’s stock after purchasing an additional 39,451 shares during the period. Wasatch Advisors LP’s holdings in OrthoPediatrics were worth $5,226,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Prosight Management LP increased its position in OrthoPediatrics by 319.2% in the third quarter. Prosight Management LP now owns 308,707 shares of the company’s stock worth $5,720,000 after purchasing an additional 235,060 shares during the period. Inceptionr LLC acquired a new position in OrthoPediatrics during the 3rd quarter valued at about $265,000. Price T Rowe Associates Inc. MD acquired a new position in OrthoPediatrics during the 4th quarter valued at about $190,000. XTX Topco Ltd bought a new position in shares of OrthoPediatrics in the 4th quarter valued at about $188,000. Finally, State of Wyoming grew its position in shares of OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after buying an additional 4,467 shares during the period. Institutional investors own 69.05% of the company’s stock.

Wall Street Analyst Weigh In

KIDS has been the subject of a number of recent research reports. Canaccord Genuity Group set a $25.00 price target on shares of OrthoPediatrics in a research note on Friday, April 24th. Truist Financial set a $17.00 target price on shares of OrthoPediatrics in a research report on Friday, May 1st. BTIG Research restated a “buy” rating and issued a $24.00 price target on shares of OrthoPediatrics in a research report on Friday, May 1st. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Finally, Wall Street Zen raised OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.44.

OrthoPediatrics Trading Up 3.5%

Shares of NASDAQ:KIDS opened at $20.30 on Friday. The firm has a market cap of $521.30 million, a price-to-earnings ratio of -12.08 and a beta of 1.03. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $23.70. The company’s fifty day simple moving average is $17.60 and its 200 day simple moving average is $17.47. The company has a quick ratio of 2.37, a current ratio of 5.21 and a debt-to-equity ratio of 0.29.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.04. The firm had revenue of $59.36 million for the quarter, compared to the consensus estimate of $58.28 million. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%. As a group, research analysts forecast that OrthoPediatrics Corp. will post -1.13 EPS for the current fiscal year.

OrthoPediatrics Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.